New ALS Gene Therapy Transforms Testing Across Canada

For the first time, every ALS patient in Canada now has access to genetic testing that could unlock life-changing treatment options.

A new study reveals that the approval of Qalsody, a gene-targeted therapy for ALS, has completely transformed medical practice across Canada. In just five years, genetic testing has gone from being offered mainly to patients with family history to becoming routine care for everyone diagnosed with the devastating disease.

The numbers tell a powerful story. In 2020, only one-third of Canadian doctors regularly offered genetic testing to patients with sporadic ALS, meaning cases with no family history. By 2025, that number hit 100%.

This shift matters because about 10 to 20 percent of people with sporadic ALS actually have an identifiable genetic cause. For decades, these patients went undiagnosed because doctors assumed their disease wasn't genetic.

The breakthrough came with Qalsody, conditionally approved in Canada in 2025. This RNA-based therapy targets mutations in the SOD1 gene and lowers levels of the toxic protein driving the disease. Clinical trials showed it reduced nerve damage markers, giving hope to patients who previously had no targeted treatment options.

Researchers from the Canadian ALS Research Network surveyed physicians at specialized ALS clinics in 2020, 2022, and 2025. By the final survey, 61 percent of doctors said Qalsody's approval directly influenced how they approach genetic testing.

The benefits are spreading beyond diagnosed patients. The number of physicians offering predictive testing to healthy at-risk relatives jumped from 37 percent to 61 percent. Doctors also increased monitoring of healthy people carrying ALS-causing mutations before symptoms appear, rising from 30 to 44 percent.

The Ripple Effect

This transformation shows how a single treatment breakthrough can redefine entire national medical standards. Canada's 24 specialized ALS clinics now operate under a new model where genetic information is considered essential for every patient.

The change means thousands of Canadians with ALS now have answers they never would have received before. For some, those answers come with treatment options that didn't exist just a few years ago.

As researchers work to develop more gene-targeted therapies for ALS, this universal testing approach ensures no eligible patient gets left behind. Every person diagnosed now has a chance to discover whether their disease has a genetic component and whether emerging treatments might help them.

What started as one approved therapy has sparked a medical practice revolution that's giving hope to everyone facing this challenging disease.